Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Cash from Discontinued Operations (2022 - 2023)

Pasithea Therapeutics (KTTA) has disclosed Cash from Discontinued Operations for 2 consecutive years, with 16895.0 as the latest value for Q4 2023.

  • Quarterly Cash from Discontinued Operations rose 97.8% to 16895.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was 611278.0 through Dec 2023, up 65.98% year-over-year, with the annual reading at 611278.0 for FY2023, 65.98% up from the prior year.
  • Cash from Discontinued Operations hit 16895.0 in Q4 2023 for Pasithea Therapeutics, down from 11250.0 in the prior quarter.
  • In the past five years, Cash from Discontinued Operations ranged from a high of 10698.0 in Q2 2022 to a low of 769680.0 in Q4 2022.